SURGERY WITH ADJUVANT IRRADIATION IN PATIENTS WITH PATHOLOGICAL STAGE-C ADENOCARCINOMA OF THE PROSTATE

被引:0
|
作者
PETROVICH, Z
LIESKOVSKY, G
FREEMAN, J
LUXTON, G
GROSHEN, S
FORMENTI, S
BAERT, L
CHEN, SC
SKINNER, DG
机构
[1] UNIV SO CALIF,SCH MED,DEPT UROL,LOS ANGELES,CA 90033
[2] UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033
[3] CATHOLIC UNIV LEUVEN,DEPT UROL,B-3000 LOUVAIN,BELGIUM
关键词
PROSTATIC CARCINOMA; SURGERY; ADJUVANT RADIOTHERAPY;
D O I
10.1002/1097-0142(19951101)76:9<1621::AID-CNCR2820760919>3.0.CO;2-O
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. In recent years, the routine use of prostate-specific antigen (PSA) to detect cancer of the prostate (CaP) early has renewed the controversy regarding radiotherapy versus radical prostatectomy as the superior definitive treatment. Radiotherapy alone has been reported to result in a high incidence of local recurrence, whereas on the other hand surgical treatment has resulted in a high incidence of microscopic residual tumor. The purpose of this study was to review our treatment results with radical prostatectomy followed by planned courses of postoperative irradiation in patients with pathologic Stage (PS)C disease. Methods. From 1972 to 1989, 95 patients with CaP with PS C tumors were treated with radical prostatectomy and bilateral pelvic lymphadenectomy. Pathologic stage distribution was: C1 in 26 (27%), C2 in 37 (39%), and C3 in 32 (34%) patients. The median follow-up was 6 years. All 95 study patients received postoperative pelvic irradiation as the only adjuvant treatment. Radiotherapy treated volume included the prostatic fossa and its immediate vicinity. The RT dose ranged from 33 Gy to 61.8 Gy (median, 45 Gy). Results. The overall 5- and 10-year actuarial survival rates were 94% and 73%, respectively, with the 5 and 10 year disease specific survival of 98% and 91%, respectively. Clinical and/or prostate specific antigen recurrence was 31% at 5 years and 44% at 10 years. Prostate specific antigen elevation without clinical evidence of recurrent disease was recorded in 26 (27%) patients. Seminal vesicle involvement (C3) and high Gleason's score (8-10) were the mast important factors predicting recurrence. Of the 95 patients treated, 2 had pelvic recurrence alone and I had local and distant metastatic disease. Radiotherapy was well tolerated with no clinically important morbidity. Conclusion. Based on this experience, moderate dose adjuvant radiotherapy after radical prostatectomy in patients with PS C Cap is recommended.
引用
收藏
页码:1621 / 1628
页数:8
相关论文
共 50 条
  • [1] ADENOCARCINOMA OF THE PROSTATE - PATHOLOGICAL STAGE-C .2. TREATMENT
    FLAM, T
    ZERBIB, M
    STEG, A
    DEBRE, B
    [J]. JOURNAL D UROLOGIE, 1991, 97 (7-8) : 305 - 308
  • [2] MANAGEMENT OF STAGE-C ADENOCARCINOMA OF THE PROSTATE
    LYNCH, JH
    GRAHAM, CW
    [J]. BRITISH JOURNAL OF UROLOGY, 1992, 70 : 50 - 56
  • [3] TELETHERAPY FOR STAGE-C ADENOCARCINOMA OF THE PROSTATE
    LUPU, AN
    PETROVICH, Z
    CORVALAN, J
    KATSKE, FA
    KAUFMAN, JJ
    [J]. JOURNAL OF UROLOGY, 1982, 128 (01): : 75 - 78
  • [4] SIGNIFICANCE OF NEEDLE-BIOPSY AFTER IRRADIATION FOR STAGE-C ADENOCARCINOMA OF PROSTATE
    COX, JD
    STOFFEL, TJ
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1976, : 88 - 88
  • [5] POSTOPERATIVE PROSTATE-SPECIFIC ANTIGEN LEVELS IN PATHOLOGICAL STAGE-C ADENOCARCINOMA OF THE PROSTATE IN PATIENTS TREATED WITH RADICAL PROSTATECTOMY ALONE
    ROBINOW, JS
    SCHILD, SE
    TOMERA, KM
    WOLFE, JT
    BUSKIRK, SJ
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 27 : 228 - 229
  • [6] MR IMAGING IN ADENOCARCINOMA OF THE PROSTATE IN STAGE-C DISEASE
    SCHMIDT, JD
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 1992, 158 (03) : 563 - 563
  • [7] RADICAL PROSTATECTOMY FOR PATHOLOGICAL STAGE-C PROSTATE-CANCER - INFLUENCE OF PATHOLOGICAL VARIABLES AND ADJUVANT TREATMENT ON DISEASE OUTCOME
    CHENG, WS
    FRYDENBERG, M
    BERGSTRALH, EJ
    LARSONKELLER, JJ
    ZINCKE, H
    [J]. UROLOGY, 1993, 42 (03) : 283 - 291
  • [8] NEOADJUVANT HORMONAL-THERAPY IN STAGE-C ADENOCARCINOMA OF THE PROSTATE
    ANDROS, EA
    DANESGHARI, F
    CRAWFORD, ED
    [J]. CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1993, 16 (06): : 510 - 515
  • [9] ADJUVANT RADIATION-THERAPY FOLLOWING RADICAL PROSTATECTOMY FOR PATHOLOGICAL STAGE-C PROSTATE-CANCER
    GIBBONS, RP
    JONSSON, E
    [J]. EUROPEAN UROLOGY, 1995, 27 : 24 - 25
  • [10] STAGE-C ADENOCARCINOMA OF THE PROSTATE - AN ANALYSIS OF 551 PATIENTS TREATED WITH EXTERNAL BEAM RADIATION
    ZAGARS, GK
    VONESCHENBACH, AC
    JOHNSON, DE
    OSWALD, MJ
    [J]. CANCER, 1987, 60 (07) : 1489 - 1499